Chemistry:Elironrasib

From HandWiki

Elironrasib is an investigational new drug that is being developed by REVOLUTION Medicines for the treatment of solid tumors. It is a RAS(ON) G12C-Selective KRAS inhibitor.[1][2][3][4][5]

References

  1. ↑ "Elironrasib - REVOLUTION Medicines". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800061389. 
  2. ↑ "Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade". Cancer Discovery 16 (6): 1152–1175. June 2026. doi:10.1158/2159-8290.CD-25-1616. PMID 41670434. 
  3. ↑ "RAS-GTP Inhibition Overcomes Acquired Resistance to KRASG12C Inhibitors Mediated by Oncogenic and Wild-Type RAS Activation in Non-Small Cell Lung Cancer". Cancer Research 86 (2): 467–484. January 2026. doi:10.1158/0008-5472.CAN-25-0600. PMID 41165456. 
  4. ↑ ""The RAS Dam Has Broken"". Cancer Discovery 16 (1): OF1. January 2026. doi:10.1158/2159-8290.CD-NW2025-0108. PMID 41405236. 
  5. ↑ "Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers". Journal of Medicinal Chemistry 68 (6): 6041–6063. March 2025. doi:10.1021/acs.jmedchem.4c02313. PMID 39993169. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Elironrasib&oldid=4583252"